Interview With Dr. Steven Mandel

In today’s episode, I talk with Matt Stang, CEO of Delic Corp. Delic (OTCMKTS: DELCF) is a psychedelic medicines company aiming to put a dent in the mental health crisis.
They are doing this in three ways.

First, through their ketamine clinics. Delic runs the largest ketamine network in the world, with dozens of clinics across North America. At the moment, these clinics are only providing ketamine therapy for disorders like depression, but in the future, once they become legal, Delic also plans on offering other psychedelic therapies such as psilocybin and MDMA therapy.

Second, through education. Delic runs multiple media platforms, such as RealitySandwich.com. These media platforms aim to educate and entertain, leading towards the destigmatization of psychedelics in our culture. As many of the people behind Delic Corp were behind the legendary High Times Magazine, this is an area of expertise for the company. Ultimately, psychedelic compounds will never succeed as medicines if society does not get behind them. Delic also has podcasts, and they host psychedelic medicine events.

And third, through science. Delic Labs is currently working on creating next generation psychedelics. Delic Labs also works with third parties, completing research, which allows the labs to run on a profit.

Taken together, Delic is not only a core player in the psychedelics movement, but they are also one of the companies making a solid revenue.

Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Video editing: @themyaholy @Psy_holy

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

Full Disclosure: This video is for entertainment only and shouldn’t be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor, Psychedelic Spotlight, and a third party. Psychedelic Spotlight and The Psychedelic Investor were hired for this video, on December 3rd, 2021, to publicly disseminate information about (DELIC CORP) via digital communications. We have been paid ($2000 CAD).

#Delic #Psychedelics #Ketamine

Big Week For Psychedelic Stocks: Field Trip Uplists to Nasdaq, Cybin Uplists to NYSE & Mydecine Files A NEW MDMA Patent!

On July 23, Field Trip Health, (FTRP: TSX), ( FTRPF: OTC), announced that they received conditional approval from The NASDAQ Stock Market to uplist to the Global Select Tier of that market, subject to fulfilling any remaining conditions as required by NASDAQ. The date for the uplisting is still to be confirmed, though we should expect an announcement shortly.

Cybin Inc., (CYBN: NEO), ( CLXPF: OTC), also announced that they received conditional approval to uplist to the NYSE. Like with Field Trip, this uplisting to the NYSE is still conditional on several technicalities, so it is not a 100% done deal yet. Once these procedural steps have been taken, a date will be announced.

In other news, Mydecine, (MYCO: NEO), (MYCOF: OTC), has announced that the company has filed a patent to include MDMA-like molecules. This is exciting, because MDMA to treat PTSD is one of the most exciting applications of psychedelic therapy and the results from the most recent MAPS study looking at MDMA to treat PTSD were groundbreaking.

Links:
FIELD TRIP HEALTH LTD. OBTAINS CONDITIONAL APPROVAL TO LIST ON NASDAQ UNDER THE SYMBOL “FTRP”:
https://thepsychedelicinvestor.com/2021/07/23/field-trip-health-ltd-obtains-conditional-approval-to-list-on-nasdaq-under-the-symbol-ftrp/

CYBIN ANNOUNCES CONDITIONAL LISTING APPROVAL FROM NYSE AMERICAN:
https://thepsychedelicinvestor.com/2021/07/23/cybin-announces-conditional-listing-approval-from-nyse-american/

MYDECINE EXPANDS PORTFOLIO OF NOVEL MOLECULES FILING NEW PATENT FOR MDMA-LIKE COMPOUNDS:
https://thepsychedelicinvestor.com/2021/07/24/mydecine-expands-portfolio-of-novel-molecules-filing-new-patent-for-mdma-like-compounds/

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#FieldTripHealth #Cybin #Mydecine